ARTICLE | Clinical News
RG2417: Completed Phase IIb enrollment
October 11, 2010 7:00 AM UTC
Repligen completed enrollment of 175 patients in a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIb trial evaluating twice-daily 500 mg oral RG2417 for 8 weeks. ...